Top marijuana regulators from a growing number of states are complaining that federal officials are not providing enough—or any—guidance about the Trump administration’s move to federally reschedule cannabis.
Moving marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III is the biggest change to federal cannabis policy in decades, and state officials say they could use help understanding its implications for business registration, taxes and packaging requirements for cannabis products.
Last week, for example, Georgia regulators approved a number of changes to state medical cannabis rules, including one concerning safety and warning label requirements for products. The federal marijuana rescheduling order included a provision specifying that medical marijuana is subject to a federal rule requiring labels to include a “clear, concise warning that it is a crime to transfer the drug to any person other than the patient.”
Andrew Turnage, executive director of the Georgia Access to Medical Cannabis Commission (GMCC), said at the meeting last week that he and his staff have attempted to coordinate with the Drug Enforcement Administration (DEA) to ensure that the new state rules are in accordance with the federal requirement, to no avail.
“We want to do our best to align
Read full article on Marijuana Moment
